Drugs / CHF6333
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04010799 | May 2019 → Mar 2021 | bronchiectasis, cystic fibrosis | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT03056326 | Nov 2016 → Jul 2017 | bronchiectasis, cystic fibrosis | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06166056 | Nov 2023 → Aug 2026 overdue | bronchiectasis | Chiesi Farmaceutici S.p.A. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHF6333 | “CHF6333 Active (part I - SAD). Once daily inhaled single dose of CHF6333 at each period (three dose level).” NCT04010799 ↗ |
| Action | Inhibit | “inhibitor of HNE” NCT03056326 ↗ |
| Route | Inhaled | “inhaled CHF6333 DPI” NCT03056326 ↗ |